{"schema_version":"secwatch.filing_event.v1","accession":"0001178913-23-000679","form_type":"8-K","ticker":"CMMB","cik":"0001534248","company_name":"Chemomab Therapeutics Ltd.","filed_at":"2023-02-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.474162+00:00","generated_at":"2026-06-19T06:53:30.137686+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Chemomab receives FDA clearance to start Phase 2 trial of CM-101 in systemic sclerosis","bullets":["FDA cleared IND for Phase 2 ABATE trial of CM-101 in systemic sclerosis (SSc).","CM-101 is a first-in-class monoclonal antibody targeting CCL24; has Orphan Drug designation for SSc and PSC.","Trial to enroll 45 patients; primary endpoint safety; top-line data expected H2 2024.","CM-101 previously well-tolerated in early trials, reduced fibro-inflammatory biomarkers."],"urls":{"canonical":"https://secwatch.observer/filing/0001178913-23-000679","json":"https://secwatch.observer/filing/0001178913-23-000679.json","markdown":"https://secwatch.observer/filing/0001178913-23-000679.md","text":"https://secwatch.observer/filing/0001178913-23-000679.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1534248/000117891323000679/0001178913-23-000679-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1534248/000117891323000679/form8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T06:53:30.137686+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}